Read more
4:38 PM · 9 August 2021

BioNTech stock soars after Q2 earnings beat

BioNTech
Stocks
BNTX.US, BioNTech SE - ADR
-
-

Shares of the Covid-19 vaccine maker BioNTech (BNTX.US) skyrocketed during today’s US session after the company released its Q2 results (today, before the opening bell). The company said that it and its partner Pfizer (PFE.US) had shipped roughly 1 billion doses of their coronavirus vaccine as of late July. Both companies have signed orders for delivery of more than 2.2 billion doses this year. 

BioNTech earned $12.67 per share on $6.24 billion second-quarter sales. Results topped expectations as Wall Street anticipated earnings of $8.87 per share on $3.83 billion of revenues. The company’s CEO says that currently the best approach is to continue with a booser dose of the existing vaccine, but the situation may also require adaptation of the vaccine amid further variants. Also, the firm hinted at potential M&A plans as well as licensing of products and strategic collaborations in order to boost its pipeline of cancer drugs.

BioNTech (BNTX.US) shares have risen more than 100% over the past… month! Earlier the stock was trading in an upward channel, but a breakout followed. At press time the price is soaring 15% and the daily candlestick shows that bulls remain in control during today’s trading. Source: xStation5

5 December 2025, 3:30 PM

Netflix buys up Warner Bros - What does it mean for streaming and markets?

5 December 2025, 3:11 PM

US Open: US indices gain after PCE data 🗽Semiconductor stocks surge

5 December 2025, 11:42 AM

DE40: Adequate data, Mild growth

5 December 2025, 9:04 AM

Chart of the day: CHN.cash (05.12.2025)

Join over 2 000 000 XTB Group Clients from around the world

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits